Yung Zip Chemical Ind. Co., Ltd.

TPEX:4102 Stok Raporu

Piyasa değeri: NT$1.4b

Yung Zip Chemical Ind Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Yung Zip Chemical Ind has been growing earnings at an average annual rate of 29.3%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 8.2% per year. Yung Zip Chemical Ind's return on equity is 12.7%, and it has net margins of 15.1%.

Anahtar bilgiler

29.3%

Kazanç büyüme oranı

29.3%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi18.5%
Gelir büyüme oranı8.2%
Özkaynak getirisi12.7%
Net Marj15.1%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Apr 29
Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 04
Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Jan 28
Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly

Are Yung Zip Chemical Ind's (GTSM:4102) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 22
Are Yung Zip Chemical Ind's (GTSM:4102) Statutory Earnings A Good Guide To Its Underlying Profitability?

Should Weakness in Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Nov 25
Should Weakness in Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Gelir ve Gider Dağılımı

Yung Zip Chemical Ind nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

TPEX:4102 Gelir, gider ve kazançlar (TWD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24611928533
31 Mar 24574728534
31 Dec 23559638434
30 Sep 23588678435
30 Jun 23577598335
31 Mar 23595838335
31 Dec 22567708135
30 Sep 22533517533
30 Jun 22496357132
31 Mar 22478146732
31 Dec 2147866631
30 Sep 21460126933
30 Jun 21483137135
31 Mar 21466107434
31 Dec 20463317333
30 Sep 20439307133
30 Jun 20427396831
31 Mar 20419426531
31 Dec 19417316431
30 Sep 19429266229
30 Jun 19422166028
31 Mar 19389-25827
31 Dec 18357-155626
30 Sep 18324-125726
30 Jun 18311-115625
31 Mar 18312-185824
31 Dec 17314-255924
30 Sep 17301-385422
30 Jun 17279-645422
31 Mar 17280-695123
31 Dec 16268-685022
30 Sep 16285-635224
30 Jun 16306-285225
31 Mar 16312-205228
31 Dec 15318-285428
30 Sep 15307-385328
30 Jun 15299-505327
31 Mar 15285-625325
31 Dec 14277-665225
30 Sep 14285-655327
30 Jun 14278-1025328
31 Mar 14278-875428
31 Dec 13300-675531

Kaliteli Kazançlar: 4102 has high quality earnings.

Büyüyen Kar Marjı: 4102's current net profit margins (15.1%) are higher than last year (10.2%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4102 has become profitable over the past 5 years, growing earnings by 29.3% per year.

Büyüme Hızlandırma: 4102's earnings growth over the past year (57.1%) exceeds its 5-year average (29.3% per year).

Kazançlar vs. Sektör: 4102 earnings growth over the past year (57.1%) exceeded the Pharmaceuticals industry -0.6%.


Özkaynak Getirisi

Yüksek ROE: 4102's Return on Equity (12.7%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin